Overview

CONSHOHOCKEN, Pa. , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH),

This final read-out of the 52-week open-label resmetirom 100 mg treatment study of 171 patients with presumed non-alcoholic steatohepatitis ( NASH ) and fibrosis, identified using non-invasive tests, demonstrate that resmetirom: provided rapid and sustained reduction in liver fat and liver volume;

Several abstracts with data from the open-label arm of the Phase 3 MAESTRO-NAFLD-1 study accepted for presentation at AASLD’s upcoming The Liver Meeting® 2021 CONSHOHOCKEN, Pa. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate